

The "two week wait" referral pathway allows prompt treatment but does not improve outcome for patients with oesophagogastric cancer

D. Sharpe, R.N. Williams, S.S. Ubhi, C.D. Sutton, D.J. Bowrey

▶ To cite this version:

D. Sharpe, R.N. Williams, S.S. Ubhi, C.D. Sutton, D.J. Bowrey. The "two week wait" referral pathway allows prompt treatment but does not improve outcome for patients with oesophagogastric cancer. EJSO - European Journal of Surgical Oncology, 2010, 36 (10), pp.977. 10.1016/j.ejso.2010.07.002 . hal-00625562

HAL Id: hal-00625562 https://hal.science/hal-00625562

Submitted on 22 Sep 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: The "two week wait" referral pathway allows prompt treatment but does not improve outcome for patients with oesophagogastric cancer

Authors: D. Sharpe, R.N. Williams, S.S. Ubhi, C.D. Sutton, D.J. Bowrey

PII: S0748-7983(10)00306-9

DOI: 10.1016/j.ejso.2010.07.002

Reference: YEJSO 3020

To appear in: European Journal of Surgical Oncology

Received Date: 20 October 2009

Revised Date: 22 June 2010

Accepted Date: 15 July 2010

Please cite this article as: Sharpe D, Williams RN, Ubhi SS, Sutton CD, Bowrey DJ. The "two week wait" referral pathway allows prompt treatment but does not improve outcome for patients with oesophagogastric cancer, European Journal of Surgical Oncology (2010), doi: 10.1016/ j.ejso.2010.07.002

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ORIGINAL ARTICLE

THE "TWO WEEK WAIT" REFERRAL PATHWAY ALLOWS PROMPT TREATMENT BUT DOES NOT IMPROVE OUTCOME FOR PATIENTS

WITH OESOPHAGOGASTRIC CANCER

D. Sharpe

R.N. Williams

S.S. Ubhi

C.D. Sutton

D.J. Bowrey

University Hospitals of Leicester NHS Trust

Department of Surgery, Leicester Royal Infirmary, United Kingdom

Correspondence to: D.J. Bowrey,

Consultant general surgeon specialising in oesophagogastric & weight loss surgery,

Honorary Senior Lecturer

Department of Surgery, Level 6 Balmoral Building, Leicester Royal Infirmary

Infirmary Square, Leicester, LE1 5WW

Tel: +44 (0) 116 258 5997 Fax: +44 (0) 116 258 6083

E-mail: djb57@le.ac.uk

Presented at the Association of Upper Gastrointestinal Surgeons of Great Britain and

Ireland meeting, September 2008 and published in abstract form in Br J Surg 2008;

95(S7): 41

ABSTRACT

Introduction: The Two Week Wait Referral Service (2WW) has been implemented as a means of fast-tracking patients with suspected upper gastrointestinal cancers for endoscopy. Whether or not it impacts on the outcome of these patients is unclear. The aim of this study was to compare the outcome of patients referred through 2WW with that of patients with oesophago-gastric cancer identified through alternate referral pathways (routine, emergency).

Methods: The study population was 340 patients with oesophago-gastric carcinoma (gastric 154) diagnosed during the time period 01/2006-12/2007 at University Hospitals of Leicester NHS Trust. Data were collected prospectively by the MDT co-ordinator and analysed retrospectively.

Results: 135 of the 340 patients with oesophago-gastric cancer were diagnosed through the 2WW, 115 patients through routine referral pathways, and 90 patients were admitted on an emergency basis. Patients referred through 2WW had a median referral to 1^{st} treatment time of 47 days (routine 79, emergency 28, p<0.001 all group comparisons). The number of patients treated with potentially curative intent was 37 of 135 for the 2WW, 42 of 115 for the routine referrals and 10 of 90 for patients admitted as emergencies. The corresponding median survivals for the groups were 239 days (2WW), 405 days (routine) and 121 days (emergency), p<0.001 (log rank).

Conclusions: Referral by 2WW resulted in more rapid treatment than routine referral but this did not translate into an improvement in survival. This suggests that the targeting of endoscopy to patients with alarm symptoms is flawed and a less selective approach should be promoted if curable cancers are to be detected.

Keywords: esophageal neoplasms; stomach neoplasms; survival; two-week wait

INTRODUCTION

The Two Week Wait Referral Pathway was introduced into the United Kingdom in 2000 in order to fast-track patients with "alarm symptoms" to the appropriate diagnostic investigation.[1] This referral pathway ensures that patients with suspected cancers are seen by a specialist within two weeks of primary care consultation. The premise underpinning this referral system was two-fold, firstly, the assertion that earlier diagnosis would result in the diagnosis of earlier stage disease and secondly, that patient anxiety would be lessened. In spite of its nationwide application, surprisingly little has been reported supporting its use. The National Cancer Plan further stipulated targets of 31 days from decision to treat cancer to commencement of definitive treatment, and 62 days from primary care referral to commencement of definitive treatment.

The aim of the current study was to compare the outcome of patients with oesophago-gastric carcinoma in relation to their route of referral. This would either confirm or refute the hypothesis that the two week wait referral leads to an improved outcome for patients with oesophago-gastric carcinoma.

PATIENTS AND METHODS

Study population

The study population was 340 patients (222 male, 118 female) with gastric (n=154) or oesophageal cancer (n=186) referred through the gastro-oesophageal multidisciplinary meeting at University Hospitals of Leicester NHS Trust between 1st January 2006 and 31st December 2007. Siewert type 1 and 2 adenocarcinomas of the gastro-oesophageal junction were classified as oesophageal in origin, while Siewert type 3 junctional adenocarcinomas were classified as gastric in origin. Patients with non-epithelial malignancy were excluded. Patients were categorised into one of the following three groups according to their route of referral to the hospital: emergency admission, routine referral (outpatient or open access endoscopy), or two-week wait referral.

Referral criteria

Referral criteria for the two-week wait pathway were according to the National Institute of Health and Clinical Excellence guidelines.[9] This advocates endoscopy for the "alarm symptoms" of dyspepsia, dysphagia, progressive unintentional weight loss, nausea and vomiting, epigastric mass in patients over the age of 55. Patients not satisfying these criteria are initially treated in primary care empirically with antisecretory medication or *Helicobacter pylori* eradication therapy. Endoscopy is reserved for those with uncontrolled or progressive symptoms after two months of therapy.

Treatment protocols

Treatment protocols were as previously reported.[10] In short, the standard of care for physiologically fit patients with operable cancers was surgical resection alone for T1-2 N0 disease or neoadjuvant chemotherapy followed by surgical resection for T3 N0-1 disease. Patients with T3 N0-1 squamous carcinoma of the oesophagus suitable for radical therapy were given the choice of neoadjuvant chemotherapy and surgical resection or radical chemoradiotherapy.

Data collection and statistical methods

Patient information was retrieved from the prospectively maintained electronic database and analysed retrospectively, reporting outcome according to follow-up to 1^{st} March 2010. Comparison of proportions was by X^2 test and comparison of continuous data by the Mann-Whitney U-test or the Kruskal-Wallis test. Actuarial survival was estimated using the Kaplan-Meier method, with the log rank test for comparison. Significance was assumed at the 5% level.

RESULTS

Referral pathway and influence on survival

One hundred and thirty-five of the 340 patients with oesophago-gastric cancer were diagnosed through the two-week wait system, 115 patients were diagnosed through routine outpatient or open access endoscopy referral, and 90 patients were admitted on an emergency basis.

Table 1 summarises the demographic characteristics of these three groups of patients and their outcome. The overall median survival was 251 days (95% confidence interval 209-293). The median survival for the 251 patients treated with palliative intent was 178 days (95% confidence interval 135-221), compared to a median survival time of 736 days (95% confidence interval 537-935) for the 89 patients treated with curative intent (Figure 1), X^2 =69.3, p<0.001.

Table 1 shows that patients referred through the two-week wait system had outcomes intermediate between those of patients referred routinely and those admitted as emergencies. This last group had the worst outcome of the three groups. They were older, had a higher frequency of metastatic disease, and had the poorest prognosis (Figure 2). Further, there was a higher proportion of gastric cancers and a lower proportion of UICC stages 1 and 2 disease among patients presenting as emergencies compared to the other groups.

31 day mortality

The 31 day mortality after endoscopic stenting was six of 56 patients, while among the 89 patients treated with curative intent (surgery +/- chemotherapy - 68 patients, chemoradiotherapy - 19 patients, endoscopic mucosal resection - two patients), there was one postoperative death.

Delays in the patient journey

Table 2 summarises the time intervals for each point of the patient journey. Patients referred through the two week wait pathway had significantly shorter delays compared to those referred through routine channels.

DISCUSSION

The principal study findings were that patients referred through the two week wait referral pathway were treated more promptly than those referred for routine outpatient clinic or open access endoscopy appointments, although this did not translate into an improved cancer survival.

Literature reporting on two-week wait referral pathway

Table 3 summarises the published literature on the two-week wait referral pathway for all cancer sites. There is surprisingly little information on patients with oesophago-gastric cancer. The table indicates that the cancer yield is low, a median of 10% and that the proportion of cancers identified by this pathway is likewise small, a median of 33%. Our data are in broad agreement with this, with 40% of cancers being identified via this route. The current study has not addressed the cancer detection rate of the two-week wait system, but the authors have previously reported this to be 3% in an analogous, but different cohort.[11] A large primary care study likewise reported a 3% prevalence of oesophagogastric cancer among those with alarm symptoms.[12]

Delays in diagnosis

Patients with cancer diagnosed through "routine" referral pathways experienced significantly longer delays than the other groups of patients, on average three months from initial referral to diagnosis. In spite of this, they had a better prognosis. These patients presented with symptoms indistinguishable from benign upper gastrointestinal pathology. In sharp contrast to this, patients presenting as emergencies fared poorly. This has been noted in previous reports.[13] This group of patients had a lower frequency of UICC stages 1 and 2 disease (15%) compared to the

other two groups (31-32%) and the high early cancer mortality in this group was striking. Further, gastric cancer more frequently presented on the emergency intake. This broadly reflected admission with the complications of upper gastrointestinal haemorrhage or the presence of an abdominal mass.

The Cancer Plan was set up with the premise that earlier diagnosis of cancer would lead to an improved outcome.[1] However, the evidence supporting a link between delay in diagnosis and poorer cancer outcome is weak.[14-25] The greatest number of studies examining diagnostic delays have been in patients with breast cancer. The majority of these studies have failed to identify an association between delay in diagnosis and prognosis. Further, these studies have shown that the majority of the delay occurs before the patient accesses the healthcare system rather than afterwards. Nonetheless, on ethical and humanistic grounds, there are compelling arguments to facilitate early diagnosis.

What this audit has not addressed nor have most of previous reports is the impact on quality of life of the two-week wait referral system. Intuitively, one would expect shorter diagnostic delays to cause less emotional and psychological distress to patients. Further studies should focus on these domains.

Conclusions

In conclusion, although it has provided prompt access to specialist services, the twoweek wait referral pathway has not resulted in an improved survival compared to routine referral pathways. Further, the majority of oesophago-gastric cancers (60%) at our institution were diagnosed through other referral pathways. More liberal use of unselected endoscopy or screening, targeting the younger population, such as those aged 70 years or less, is likely the only way in which earlier diagnosis of oesophago-

gastric cancer and an improved outcome will be achieved. Although this will incur additional costs, these could be offset by a more pragmatic approach to investigation in patients not suitable for radical therapy. The median age of patients referred through the two-week wait system in our population was 75 years. Many of these patients would only be suitable for palliative treatments, irrespective of the cancer stage.

Chillip Mark

Referral pathway	Routine	Two-week	Emergency	
	(n=115)	wait (n=135)	(n=90)	
Median age in years (range)	71 (37-88) ^a	75 (40-96)	77 (36-97)	
Younger than age 55: <i>n</i>	12 9		11	
Sex (male:female)	77:38	83:52	62:28	
Cancer site (oesophagus:stomach)	67:48	81:54	38:52 ^b	
UICC stage (1:2:3:4) : <i>n</i>	11:25:40:36	6:35:53:37	2:10:32:37 ^c	
Treated with curative intent: <i>n</i>	42	37	10 ^d	
Death < 31 days of referral: n	6	6	23 ^e	
Median survival in days (95% CI) ^f	405	239	121	
	(305-505)	(188-289)	(58-184)	

Table 1: Outcome according to route of patient referral

For 16 bed bound patients treated palliatively, it was considered that staging investigations would not influence treatment and no cross-sectional imaging and formal UICC staging was obtained.

^dNote that in the results section, the median survival of these 89 patients (referral pathway: routine, 42; two-week wait, 37; emergency 10) treated with potentially curative intent was compared to the outcome of the remaining 251 patients treated with palliative intent (referral pathway: routine, 73; two-week wait, 98; emergency, 80).

^ap=0.002 vs. emergency & p=0.007 vs. 2WW; ^bp=0.03 vs. routine & p=0.01 vs. 2WW; ^cp=0.03 vs. routine & p=0.02 vs. 2WW; ^dp<0.001 vs. routine & p=0.005 vs. 2WW; ^ep<0.001 vs. routine & 2WW; ^fp<0.001

^a Referral pathway	Routine	Two-week	Emergency
	(n=115)	wait (n=135)	(n=90)
Department of Health Cancer Wait To	urgets		
Referral to 1 st hospital visit	19 (0-76)	12 (5-20)	0 (0-5)
Referral to 1 st treatment	79 (19-160)	47 (20-88)	28 (9-117)
Decision to treat to 1 st treatment	9 (0-26)	6 (0-16)	2 (0-19)

Table 2: Time intervals in days for each stage of the Care Pathway

Values shown are medians and 95% confidence intervals

^ap<0.001 for all comparisons, except 2WW decision to treat to 1st treatment time,

p=0.001 vs. emergency & p=0.05 vs. routine

Note that those values shown are the unadjusted absolute time intervals. For the purposes of compliance with the cancer target waits, the time intervals are adjusted if the patient cancels or reschedules an appointment, defers admission to hospital, wishes to have a period of time to consider treatment options, or if the patient is unfit for treatment until additional intervention has been received (eg. nutritional supplementation).

Table 3: Summary of literature reporting on cancer detection rates among

patients referred through two-week wait (2WW) pathway

Cancer site	Time	% of cancers	Prevalence of
	period	diagnosed via	cancer in 2WW
		2WW	cohort
Breast	1998-9		20%
Colon	2000-1	33%	14%
Colon	2000-1		10%
Head & neck	2001-3	33%	6%
Oesophagogastric	2000-2	15%	6%
Colon	2004-5	34%	2%
Breast	1999-2005	73%	10%
	Breast Colon Colon Head & neck Oesophagogastric Colon	periodBreast1998-9Colon2000-1Colon2000-1Head & neck2001-3Oesophagogastric2000-2Colon2004-5	perioddiagnosed viaBreast1998-9Colon2000-1Colon2000-1Head & neck2001-3Oesophagogastric2000-2Loon2004-5State34%

REFERENCES

[1] The NHS Cancer Plan. Department of Health 2000.

http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAn dGuidance/DH 4009609

[2] Khawaja AR, Allan SM. Has the breast cancer "two week wait" guarantee for assessment made any difference? *Eur J Surg Oncol* 2000;26:536-9.

[3] Chohan DPK, Goodwin K, Wilkinson S, Miller R, Hall NR. How has the "twoweek wait" rule affected the presentation of colorectal cancer? *Colorectal Dis* 2005;7:450-3.

[4] Glancy DG, Card M, Sylvester PA, Thomas MG, Durdey P, Callaway M, Virjee J. Fast-track barium enema: meeting the two-week wait rule for patients with suspected colorectal cancer. *Colorectal Dis* 2005;7:241-4.

[5] Shah HV, Williams RW, Irvine GH. Fast-track referrals for oral lesions: a prospective study. *Br J Oral Maxillofac Surg* 2006;44:207-8.

[6] Spahos T, Hindmarsh A, Cameron E, Tighe MR, Igali L, Pearson D, Rhodes M,
Lewis MPN. Endoscopy waiting times and impact of the two week wait scheme on
diagnosis and outcome of upper gastrointestinal cancer. *Postgrad Med J* 2005;81:728-30.

[7] John SKP, Jones OM, Horseman N, Thomas P, Howell RD, Fozard JBJ. Inter general practice variability in use of referral guidelines for colorectal cancer. *Colorectal Dis* 2007;9:731-5.

[8] Potter S, Govindarajulu S, Shere M, Braddon F, Curran G, Greenwood R, Sahu AK, Cawthorn SJ. Referral patterns, cancer diagnoses, and waiting times after introduction of two week wait rule for breast cancer: prospective cohort study. *BMJ* 2007; 335:288.

[9] Dyspepsia: managing dyspepsia in adults in primary care. National Institute for Health and Clinical Excellence, Holborn, London, WC1V 6NA, UK.

www.nice.org.uk/CG017fullguideline

[10] Williams RN, Ubhi SS, Sutton CD, Thomas AL, Entwisle JJ, Bowrey DJ. The early use of PET-CT alters the management of patients with esophageal cancer. *J Gastrointest Surg* 2009;113:868-73.

[11] Bowrey DJ, Griffin SM, Wayman J, Karat D, Hayes N, Raimes SA. Use of alarm symptoms to select dyspeptics for endoscopy causes patients with curable esophagogastric cancer to be overlooked. *Surg Endosc* 2006; 20:1725-8.

[12] Jones R, Charlton J, Latinovic R, Gulliford MC. Alarm symptoms and identification of non-cancer diagnoses in primary care: cohort study. *BMJ* 2009; 339:b3094.

[13] Blackshaw GR, Barry JD, Edwards P, Allison MC, Lewis WG. Open-access gastroscopy is associated with improved outcomes in gastric cancer. *Eur J Gastroenterol Hepatol* 2003;15:1333-7.

[14] Arbman G, Nilsson E, Storgren-Fordell V, Sjodahl R. A short diagnostic delay is more important for rectal cancer than for colonic cancer. *Eur J Surg* 1996; 162:899-904.

[15] Martin IG, Young S, Sue-Ling H, Johnston D. Delays in the diagnosis of oesophagogastric cancer: a consecutive case series. *BMJ* 1997; 314:467.

[16] Richards MA, Smith P, Ramirez AJ, Fentiman IS, Rubens RD. The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. *Br J Cancer* 1999;79:858-64.

[17] Sainsbury R, Johnston C, Haward B. Effect on survival of delays in referral of patients with breast cancer symptoms: a retrospective analysis. *Lancet* 1999;353:1132-5.

[18] Tartter PI, Pace D, Frost M, Bernstein JL. Delay in the diagnosis of breast cancer. *Ann Surg* 1999;229:91-6.

[19] Arndt V, Sturmer T, Stegmaier C, Ziegler H, Dhom G, Brenner H. Patient delay and stage of diagnosis amond breast cancer patients in Germany – a population based study. *Br J Cancer* 2002;86:1034-40.

[20] Langenbach MR, Schmidt J, Neumann J, Zirngibl H. Delay in treatment of colorectal cancer: multifactorial problem. *World J Surg* 2003; 27:304-8.

[21] Love RR, Duc NB, Baumann LC, Anh PTH, To TV, Qian Z, Havighurst TC.

Duration of signs and survival in premenopausal women with breast cancer. *Breast Cancer Res Treatment* 2004; 86:117-24.

[22] Hardin C, Pommier S, Pommier RF. The relationships among clinician delay of diagnosis of breast cancer and tumor size, nodal status, and stage. *Am J Surg* 2006; 192:506-8.

[23] Korsgaard M, Pedersen L, Sorensen HT, Laurberg S. Reported symptoms, diagnostic delay and stage of colorectal cancer: a population-based study in Denmark. *Colorectal Dis* 2006;8:688-95.

[24] Kotz BS, Croft S, Ferry DR. Do delays between diagnosis and surgery in resectable oesophageal cancer affects survival? A study based on West Midlands cancer registry data. *Br J Cancer* 2006;95:835-40.

[25] Redondo M, Rodrigo I, Pereda T, Funez R, Acebal M, Perea-Milla E, Jimenez E. Prognostic implications of emergency admission and delays in patients with breast cancer. *Support Care Cancer* 2009;17:595-9.

LEGEND FOR FIGURES

Figure 1: Plot of overall survival from date of diagnosis for patients treated according to curative (n=89) or palliative (n=251) intent.

Figure 2: Plot of overall survival from date of diagnosis for patients stratified by referral pathway into routine (n=115), open access (n=135) or emergency (n=90).




Figure 1




Figure 2